BioMarin/$BMRN
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About BioMarin
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Ticker
$BMRN
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
3,040
Website
BioMarin Metrics
BasicAdvanced
$11B
22.14
$2.70
0.17
-
Price and volume
Market cap
$11B
Beta
0.17
52-week high
$94.85
52-week low
$52.93
Average daily volume
2M
Financial strength
Current ratio
5.52
Quick ratio
3.202
Long term debt to equity
10.281
Total debt to equity
10.39
Interest coverage (TTM)
59.46%
Profitability
EBITDA (TTM)
803.618
Gross margin (TTM)
79.74%
Net profit margin (TTM)
17.76%
Operating margin (TTM)
24.15%
Effective tax rate (TTM)
22.31%
Revenue per employee (TTM)
$970,000
Management effectiveness
Return on assets (TTM)
6.35%
Return on equity (TTM)
9.64%
Valuation
Price to earnings (TTM)
22.136
Price to revenue (TTM)
3.86
Price to book
1.98
Price to tangible book (TTM)
2.14
Price to free cash flow (TTM)
18.361
Free cash flow yield (TTM)
5.45%
Free cash flow per share (TTM)
325.47%
Growth
Revenue change (TTM)
19.36%
Earnings per share change (TTM)
152.30%
3-year revenue growth (CAGR)
16.22%
10-year revenue growth (CAGR)
13.93%
3-year earnings per share growth (CAGR)
132.76%
10-year earnings per share growth (CAGR)
9.51%
What the Analysts think about BioMarin
Analyst ratings (Buy, Hold, Sell) for BioMarin stock.
Bulls say / Bears say
BioMarin's acquisition of Inozyme Pharma for $270 million enhances its enzyme therapy portfolio, potentially expanding its market reach and revenue streams. (biomarin.com)
The company reported a 15% year-over-year increase in Q1 2025 revenues, driven by strong performance of VOXZOGO, indicating robust financial health. (biomarin.com)
Analysts from TD Cowen and J.P. Morgan have maintained 'Buy' ratings for BioMarin, reflecting confidence in the company's growth prospects. (markets.businessinsider.com)
BioMarin's Roctavian faces commercial challenges despite positive clinical results, which could impact revenue projections. (insights.citeline.com)
The company was removed from the Russell 1000 Defensive Index as of June 30, 2025, potentially affecting its attractiveness to certain institutional investors. (marketscreener.com)
Speculation about potential takeovers may introduce uncertainty and volatility in BioMarin's stock performance. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
BioMarin Financial Performance
Revenues and expenses
BioMarin Earnings Performance
Company profitability
BioMarin News
AllArticlesVideos
It is time for a move higher in biotech, says Mizuho's Jared Holz
CNBC Television·3 weeks ago
2 top value stocks to buy for second half of 2025
Finbold·2 months ago
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioMarin stock?
BioMarin (BMRN) has a market cap of $11B as of July 25, 2025.
What is the P/E ratio for BioMarin stock?
The price to earnings (P/E) ratio for BioMarin (BMRN) stock is 22.14 as of July 25, 2025.
Does BioMarin stock pay dividends?
No, BioMarin (BMRN) stock does not pay dividends to its shareholders as of July 25, 2025.
When is the next BioMarin dividend payment date?
BioMarin (BMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for BioMarin?
BioMarin (BMRN) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.